Meyka Pro banner
20/20 Biolabs Inc.

20/20 Biolabs Inc. (NASDAQ: AIDX) Stock Competitors & Peer Comparison

See AIDX's competitors and their performance on the NASDAQ and across the wider stock market.

AIDXNASDAQ
HealthcareMedical - Care Facilities
$0.49
$0.02(4.10%)
U.S. Market opens in 34h 59m

Peer Comparison Table: Medical - Care Facilities Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for AIDX and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
AIDX$0.49-4.10%2.8M-0.93-$0.53N/A
HCA$382.19+1.51%84.8B13.20$28.96+0.78%
THC$233.20+17.17%20.1B13.53$17.24N/A
DVA$235.44+0.50%15.1B20.06$11.73N/A
SOLV$78.01+1.00%13.5B12.50$6.24N/A
FMS$24.59+0.61%13.2B9.76$2.52+3.52%
EHC$112.89+1.65%11.2B19.83$5.69+0.67%
ENSG$172.99+3.27%10.1B25.07$6.90+0.15%
UHS$155.75+2.96%9.8B6.91$22.54+0.51%
OSH$39.00+0.08%9.5B-17.65-$2.21N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

HCA Healthcare, Inc. (NYSE: HCA)

AIDX vs HCA Comparison July 2026

20/20 Biolabs Inc. (NASDAQ: AIDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIDX stands at 2.8M. In comparison, HCA has a market cap of 84.8B. Regarding current trading prices, AIDX is priced at $0.49 on the NASDAQ, while HCA trades at $382.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIDX currently has a P/E ratio of -0.93, whereas HCA's P/E ratio is 13.20. In terms of profitability, AIDX's ROE is +0.79%, compared to HCA's ROE of -1.54%. Regarding short-term risk, AIDX is less volatile compared to HCA. This indicates lower risk in terms of short-term price fluctuations for AIDX.Check HCA's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions